LXRX•benzinga•December 20, 2024 at 09:34 PM

Lexicon Receives Complete Response Letter for Zynquista; Says This Expected Communication From The FDA Aligns With Previously Disclosed Strategic Decision To Discontinue Launch Preparations For Zynquista And Focus Solely On Its Clinical Development Pipeli

No summary available.

Read the full article from the original source for complete details and context.

Article published on December 20, 2024 by benzinga